Clinical Trials

1,407 enrolled

Breast Neoplasms

NCT05399329 2026-04-09

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

693 enrolled

Breast Neoplasms

NCT06962969 2026-04-02

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

1 enrolled

Breast Neoplasms

NCT04654208 2026-03-31

SIRI

Recruiting

1,500 enrolled

Breast Neoplasms

NCT07493291 2026-03-30

PALLAS-IRAQ

100 enrolled

Breast Neoplasms

NCT04671615 2025-12-10

A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

559 enrolled 26 charts

Breast Neoplasms

NCT04735367 2025-12-09

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

42 enrolled 7 charts

Breast Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

1 enrolled

Breast Neoplasms

NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

779 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT07096024 2025-08-28

A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market

1,772 enrolled

Breast Neoplasms

NCT06307457 2025-06-29

A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

604 enrolled 20 charts

Breast Neoplasms

NCT07008508 2025-06-06

BRAVE-Cyclin

BreastClassical hematology

300 enrolled

Breast Neoplasms, Cardiovascular Diseases, Venous Thromboembolism

NCT06805812 2025-02-03

PALMARES-2

Recruiting

3,500 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT06525675 2024-12-13

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

419 enrolled

Breast Neoplasms

NCT05012644 2024-10-08

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

197 enrolled 16 charts

Breast Neoplasms

NCT06607601 2024-09-23

CARE Initiative: Real-world Emulation of the PALOMA-2 Trial

724 enrolled

Breast Neoplasms, Neoplasms

NCT04176354 2024-08-23

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

813 enrolled 11 charts

Breast Neoplasms

NCT05361655 2024-06-07

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

2,888 enrolled 17 charts

Breast Neoplasms

NCT06003114 2024-05-16

A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

472 enrolled

Breast Neoplasms

NCT06338644 2024-03-29

Palbociclib

Not yet recruiting

100 enrolled

Breast Neoplasms

NCT05043506 2024-03-27

EUCHARIS

1,939 enrolled

Breast Neoplasms

NCT05584644 2023-12-19

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

150 enrolled 26 charts

Breast Neoplasms

NCT06076772 2023-10-11

Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients

Not yet recruiting

54 enrolled

Breast Neoplasms

NCT04916509 2023-06-06

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

258 enrolled

Breast Neoplasms

NCT05135104 2023-05-17

PALBO

650 enrolled

Breast Neoplasms

NCT03285568 2023-03-31

Patterns of Prescribing and Monitoring of Palbociclib

67 enrolled

Breast Neoplasms

NCT03921866 2023-03-17

ROIS

191 enrolled 91 charts

Breast Neoplasms

NCT04874025 2022-08-08

PALBOSPAIN

815 enrolled

Breast Neoplasms

NCT04992156 2022-05-19

Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

50 enrolled

Breast Neoplasms

NCT05153135 2021-12-21

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

4,320 enrolled

Breast Neoplasms

NCT05141240 2021-12-16

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

4,650 enrolled

Breast Neoplasms

NCT04852081 2021-04-21

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

1,000 enrolled

Breast Neoplasms

NCT04526028 2020-08-25

Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

612 enrolled

Breast Neoplasms

NCT04524728 2020-08-24

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

191 enrolled

Breast Neoplasms, Neoplasms

NCT04289974 2020-02-28

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

100 enrolled

Breast Neoplasms

NCT04109261 2019-09-30

PALBOCOMP

237 enrolled